B-intervention	0	9	Tamoxifen
O	10	13	for
O	14	17	the
O	18	28	prevention
O	29	31	of
O	32	38	breast
O	39	45	cancer
O	45	46	:
O	47	51	late
O	52	59	results
O	60	62	of
O	63	66	the
B-location	67	74	Italian
O	75	85	Randomized
O	86	95	Tamoxifen
O	96	106	Prevention
O	107	112	Trial
O	113	118	among
O	119	124	women
O	125	129	with
O	130	142	hysterectomy
O	142	143	.

O	144	151	Initial
O	152	160	findings
O	161	163	of
O	164	167	the
O	168	175	Italian
O	176	186	Randomized
O	187	196	Tamoxifen
O	197	207	Prevention
O	208	213	Trial
O	214	219	found
O	220	222	no
O	223	232	reduction
O	233	235	in
O	236	240	risk
O	241	243	of
O	244	250	breast
O	251	257	cancer
O	258	262	with
O	263	272	tamoxifen
O	273	276	use
O	276	277	,
O	278	285	whereas
O	286	289	the
O	290	298	National
O	299	307	Surgical
O	308	316	Adjuvant
O	317	323	Breast
O	324	327	and
O	328	333	Bowel
O	334	341	Project
O	342	348	Breast
O	349	355	Cancer
O	356	366	Prevention
O	367	372	Trial
O	373	379	showed
O	380	384	that
O	385	394	tamoxifen
O	395	404	treatment
O	405	412	reduces
O	413	417	risk
O	418	420	of
O	421	429	estrogen
O	430	438	receptor
O	438	439	-
O	439	447	positive
O	448	454	breast
O	455	461	cancer
O	461	462	.

O	463	467	Here
O	468	470	we
O	471	478	present
O	479	481	an
O	482	490	extended
O	491	497	follow
O	497	498	-
O	498	500	up
O	501	503	of
O	504	507	the
O	508	515	Italian
O	516	521	trial
O	521	522	.

O	523	527	From
O	528	535	October
O	536	537	1
O	537	538	,
O	539	543	1992
O	543	544	,
O	545	547	to
O	548	556	December
O	557	559	31
O	559	560	,
O	561	565	1997
O	565	566	,
B-total-participants	567	571	5408
O	572	581	otherwise
B-eligibility	582	589	healthy
I-eligibility	590	595	women
I-eligibility	596	599	who
I-eligibility	600	603	had
I-eligibility	604	613	undergone
I-eligibility	614	626	hysterectomy
O	627	631	were
O	632	640	randomly
O	641	649	assigned
O	650	652	in
O	653	654	a
O	655	661	double
O	661	662	-
O	662	667	blind
O	668	674	manner
O	675	677	to
O	678	687	tamoxifen
O	688	689	(
O	689	691	20
O	692	694	mg
O	695	700	daily
O	700	701	)
O	702	704	or
B-control	705	712	placebo
O	713	716	for
O	717	718	5
O	719	724	years
O	724	725	.

O	726	731	Rates
O	732	734	of
O	735	741	breast
O	742	748	cancer
O	749	752	and
O	753	758	other
O	759	765	events
O	766	768	in
O	769	772	the
O	773	776	two
O	777	783	groups
O	784	788	were
O	789	797	compared
O	798	800	by
O	801	804	the
O	805	808	use
O	809	811	of
O	812	816	risk
O	817	823	ratios
O	824	825	(
O	825	828	RRs
O	828	829	)
O	830	833	and
O	834	836	95
O	836	837	%
O	838	848	confidence
O	849	858	intervals
O	859	860	(
O	860	863	CIs
O	863	864	)
O	864	865	.

O	866	871	After
O	872	874	11
O	875	880	years
O	881	883	of
O	884	890	follow
O	890	891	-
O	891	893	up
O	893	894	,
O	895	898	136
O	899	904	women
O	905	906	(
B-cv-bin-abs	906	908	74
O	909	916	placebo
O	916	917	,
B-iv-bin-abs	918	920	62
O	921	930	tamoxifen
O	930	931	)
O	932	941	developed
B-outcome	942	948	breast
I-outcome	949	955	cancer
O	956	957	(
O	957	959	RR
O	960	961	=
O	962	963	0
O	963	964	.
O	964	966	84
O	966	967	,
O	968	970	95
O	970	971	%
O	972	974	CI
O	975	976	=
O	977	978	0
O	978	979	.
O	979	981	60
O	982	984	to
O	985	986	1
O	986	987	.
O	987	989	17
O	989	990	;
O	991	997	annual
O	998	1003	rates
O	1004	1008	were
O	1009	1010	2
O	1010	1011	.
O	1011	1013	48
O	1014	1017	and
O	1018	1019	2
O	1019	1020	.
O	1020	1022	07
O	1023	1026	per
O	1027	1031	1000
O	1032	1037	women
O	1037	1038	-
O	1038	1043	years
O	1043	1044	,
O	1045	1057	respectively
O	1057	1058	)
O	1058	1059	.

O	1060	1063	The
B-outcome	1064	1069	rates
I-outcome	1070	1072	of
I-outcome	1073	1079	breast
I-outcome	1080	1086	cancer
O	1087	1089	in
O	1090	1093	the
O	1094	1097	two
O	1098	1103	study
O	1104	1110	groups
O	1111	1115	were
O	1116	1123	similar
O	1124	1129	among
O	1130	1135	women
O	1136	1139	who
O	1140	1143	had
O	1144	1147	had
O	1148	1157	bilateral
O	1158	1170	oophorectomy
O	1171	1174	and
O	1175	1180	among
O	1181	1186	women
O	1187	1189	at
O	1190	1193	low
O	1194	1198	risk
O	1199	1202	for
O	1203	1210	hormone
O	1211	1219	receptor
O	1219	1220	-
O	1220	1228	positive
O	1229	1230	(
O	1230	1232	HR
O	1232	1233	+
O	1233	1234	)
O	1235	1242	disease
O	1243	1246	but
O	1247	1251	were
O	1252	1256	much
O	1257	1262	lower
O	1263	1265	in
O	1266	1269	the
O	1270	1279	tamoxifen
O	1280	1285	group
O	1286	1291	among
O	1292	1297	women
O	1298	1300	at
O	1301	1305	high
O	1306	1310	risk
O	1311	1312	(
O	1312	1319	placebo
O	1319	1320	,
B-cv-bin-abs	1321	1322	6
I-cv-bin-abs	1322	1323	.
I-cv-bin-abs	1323	1325	26
O	1326	1329	per
B-control-participants	1330	1334	1000
O	1335	1340	women
O	1340	1341	-
O	1341	1346	years
O	1346	1347	,
O	1348	1357	tamoxifen
O	1357	1358	,
B-iv-bin-abs	1359	1360	1
I-iv-bin-abs	1360	1361	.
I-iv-bin-abs	1361	1363	50
O	1364	1367	per
B-intervention-participants	1368	1372	1000
O	1373	1378	women
O	1378	1379	-
O	1379	1384	years
O	1384	1385	;
O	1386	1388	RR
O	1389	1390	=
O	1391	1392	0
O	1392	1393	.
O	1393	1395	24
O	1395	1396	,
O	1397	1399	95
O	1399	1400	%
O	1401	1403	CI
O	1404	1405	=
O	1406	1407	0
O	1407	1408	.
O	1408	1410	10
O	1411	1413	to
O	1414	1415	0
O	1415	1416	.
O	1416	1418	59
O	1418	1419	)
O	1419	1420	.

O	1421	1427	During
O	1428	1431	the
O	1432	1441	treatment
O	1442	1448	period
O	1448	1449	,
O	1450	1455	women
O	1456	1458	in
O	1459	1462	the
O	1463	1472	tamoxifen
O	1473	1478	group
O	1479	1487	reported
O	1488	1492	more
B-outcome	1493	1496	hot
I-outcome	1497	1504	flashes
O	1505	1506	(
O	1506	1508	RR
O	1509	1510	=
O	1511	1512	1
O	1512	1513	.
O	1513	1515	78
O	1515	1516	,
O	1517	1519	95
O	1519	1520	%
O	1521	1523	CI
O	1524	1525	=
O	1526	1527	1
O	1527	1528	.
O	1528	1530	57
O	1531	1533	to
O	1534	1535	2
O	1535	1536	.
O	1536	1538	00
O	1538	1539	)
O	1539	1540	,
B-outcome	1541	1548	vaginal
I-outcome	1549	1558	discharge
O	1559	1560	(
O	1560	1562	RR
O	1563	1564	=
O	1565	1566	3
O	1566	1567	.
O	1567	1569	44
O	1569	1570	,
O	1571	1573	95
O	1573	1574	%
O	1575	1577	CI
O	1578	1579	=
O	1580	1581	2
O	1581	1582	.
O	1582	1584	90
O	1585	1587	to
O	1588	1589	4
O	1589	1590	.
O	1590	1592	09
O	1592	1593	)
O	1593	1594	,
O	1595	1598	and
B-outcome	1599	1606	urinary
I-outcome	1607	1619	disturbances
O	1620	1621	(
O	1621	1623	RR
O	1624	1625	=
O	1626	1627	1
O	1627	1628	.
O	1628	1630	52
O	1630	1631	,
O	1632	1634	95
O	1634	1635	%
O	1636	1638	CI
O	1639	1640	=
O	1641	1642	1
O	1642	1643	.
O	1643	1645	23
O	1646	1648	to
O	1649	1650	1
O	1650	1651	.
O	1651	1653	89
O	1653	1654	)
O	1655	1658	but
O	1659	1664	fewer
B-outcome	1665	1674	headaches
O	1675	1676	(
O	1676	1678	RR
O	1679	1680	=
O	1681	1682	0
O	1682	1683	.
O	1683	1685	68
O	1685	1686	,
O	1687	1689	95
O	1689	1690	%
O	1691	1693	CI
O	1694	1695	=
O	1696	1697	0
O	1697	1698	.
O	1698	1700	50
O	1701	1703	to
O	1704	1705	0
O	1705	1706	.
O	1706	1708	94
O	1708	1709	)
O	1710	1714	than
O	1715	1720	women
O	1721	1723	in
O	1724	1727	the
O	1728	1735	placebo
O	1736	1741	group
O	1741	1742	.

B-outcome	1743	1763	Hypertriglyceridemia
O	1764	1765	(
O	1765	1767	RR
O	1768	1769	=
O	1770	1771	4
O	1771	1772	.
O	1772	1774	33
O	1774	1775	,
O	1776	1778	95
O	1778	1779	%
O	1780	1782	CI
O	1783	1784	=
O	1785	1786	1
O	1786	1787	.
O	1787	1789	96
O	1790	1792	to
O	1793	1794	9
O	1794	1795	.
O	1795	1797	53
O	1797	1798	)
O	1798	1799	,
B-outcome	1800	1814	thromboembolic
I-outcome	1815	1821	events
O	1822	1823	(
O	1823	1825	RR
O	1826	1827	=
O	1828	1829	1
O	1829	1830	.
O	1830	1832	63
O	1832	1833	,
O	1834	1836	95
O	1836	1837	%
O	1838	1840	CI
O	1841	1842	=
O	1843	1844	1
O	1844	1845	.
O	1845	1847	02
O	1848	1850	to
O	1851	1852	2
O	1852	1853	.
O	1853	1855	62
O	1855	1856	)
O	1856	1857	,
O	1858	1861	and
B-outcome	1862	1869	cardiac
I-outcome	1870	1880	arrhythmia
I-outcome	1881	1883	or
I-outcome	1884	1890	atrial
I-outcome	1891	1903	fibrillation
O	1904	1905	(
O	1905	1907	RR
O	1908	1909	=
O	1910	1911	1
O	1911	1912	.
O	1912	1914	73
O	1914	1915	,
O	1916	1918	95
O	1918	1919	%
O	1920	1922	CI
O	1923	1924	=
O	1925	1926	1
O	1926	1927	.
O	1927	1929	01
O	1930	1932	to
O	1933	1934	2
O	1934	1935	.
O	1935	1937	98
O	1937	1938	)
O	1939	1943	were
O	1944	1948	also
O	1949	1953	more
O	1954	1962	frequent
O	1963	1965	in
O	1966	1969	the
O	1970	1979	tamoxifen
O	1980	1985	group
O	1986	1990	than
O	1991	1993	in
O	1994	1997	the
O	1998	2005	placebo
O	2006	2011	group
O	2011	2012	.

O	2013	2024	Appropriate
O	2025	2034	selection
O	2035	2037	of
O	2038	2043	women
O	2044	2046	at
O	2047	2051	high
O	2052	2056	risk
O	2057	2060	for
O	2061	2063	HR
O	2063	2064	+
O	2065	2072	disease
O	2073	2076	may
O	2077	2084	improve
O	2085	2088	the
O	2089	2093	risk
O	2093	2094	-
O	2094	2101	benefit
O	2102	2107	ratio
O	2108	2110	of
O	2111	2120	tamoxifen
O	2121	2133	intervention
O	2133	2134	.
